LARGON Drug Patent Profile
✉ Email this page to a colleague
When do Largon patents expire, and what generic alternatives are available?
Largon is a drug marketed by Hikma and is included in one NDA.
The generic ingredient in LARGON is propiomazine hydrochloride. Additional details are available on the propiomazine hydrochloride profile page.
Summary for LARGON
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 13 |
Patent Applications: | 49 |
Formulation / Manufacturing: | see details |
DailyMed Link: | LARGON at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for LARGON
US Patents and Regulatory Information for LARGON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hikma | LARGON | propiomazine hydrochloride | INJECTABLE;INJECTION | 012382-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |